Lyra Therapeutics, Inc. (LYRA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback